Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 24, 2022

Long-Term Safety and Effectiveness of Trastuzumab Biosimilar PF-05280014 in Patients With HER2+ Metastatic Breast Cancer

BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

 

Additional Info

BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
BioDrugs 2022 Jan 01;36(1)55-69, RK Li, E Tokunaga, H Adamchuk, V Vladimirov, E Yanez, KS Lee, I Bondarenko, A Vana, F Hilton, T Ishikawa, K Tajima, O Lipatov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading